Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age

Name: Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age
Published: 2022
License: Public Domain

GlaxoSmithKline · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

efficacy neisseria-gonorrhoeae safety sexually-transmitted-diseases

sexually transmitted diseases, neisseria gonorrhoeae, safety, efficacy, sexually transmitted infection, healthy adults 18 to 50 years of age, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age

Related documents